The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 30, 2018
Filed:
Oct. 03, 2014
Applicant:
Duke University, Durham, NC (US);
Inventors:
Kris Cameron Wood, Durham, NC (US);
Peter Saville Winter, Durham, NC (US);
Assignee:
DUKE UNIVERSITY, Durham, NC (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/7088 (2006.01); A61K 45/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/428 (2006.01); A61K 31/4375 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/4745 (2006.01); A61K 31/506 (2006.01); A61K 31/635 (2006.01); A61K 31/4178 (2006.01); A61K 31/366 (2006.01); A61K 31/404 (2006.01); A61K 31/553 (2006.01); A61K 31/675 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7088 (2013.01); A61K 31/366 (2013.01); A61K 31/404 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/428 (2013.01); A61K 31/4375 (2013.01); A61K 31/4745 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/553 (2013.01); A61K 31/635 (2013.01); A61K 31/675 (2013.01); A61K 45/06 (2013.01); G01N 33/6893 (2013.01); G01N 2333/9121 (2013.01); G01N 2800/52 (2013.01); G01N 2800/7028 (2013.01);
Abstract
Methods and compositions for diagnosing and treating JAK2 inhibitor resistant cancers are disclosed. In the disclosed methods, AKT and/or PI3K inhibitors, ERK/MEK inhibitors, BCL-XL protein inhibitors, or combinations thereof are administered to a subject to reverse JAK2 inhibitor resistance. Accordingly, compositions containing such inhibitors may be used along with JAK2 inhibitors to successfully treat JAK2 inhibitor resistant cancers.